Developed Markets Boost Zydus Cadila's Bottom Line

May 2007 | Company Finance Alert

Rocketing sales in the US and Western Europe have boosted the profit of Indian drugmaker Zydus Cadila by a very impressive 53% in the financial year ended March 31 2007. All sectors of the company performed well, with new product launches, expansion into foreign markets and a broad pipeline in place for future growth. BMI is encouraged by the financial performance of Cadila and its strategy of concentrating on generics but maintaining a research arm is model that should be emulated on the subcontinent. We expect similar, if not better financial results in

If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.